FMI HOLDINGS LTD. 6-K 2005
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
For the month of August, 2005.
Commission File Number n
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F....[X ]..... Form 40-F...[ ]...
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [ ]
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ________
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
This report on Form 6-K shall be deemed to be incorporated by reference in the prospectus included in Registration Statement on Form F-3 (File No. 333-110910) filed with the Securities and Exchange Commission and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
A Life Sciences Company
Forbes Medi-Tech Makes Valuable Addition to the Board of Directors
~Forbes Appoints Guy Miller from Edison Pharmaceuticals as Director~
Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced today the appointment of Guy Miller, CEO of Edison Pharmaceuticals, to the Forbes Medi-Tech Board of Directors.
Dr. Miller brings a successful history of R&D and operational experience in the life science industry which compliments our development and commercialization initiatives, said Charles Butt, President & CEO of Forbes Medi-Tech Inc. He will be a welcome addition to the Board as we prepare for the upcoming US Phase II trial of FM-VP4.
Guy Miller, MD, PhD, is Chief Executive Officer of Edison Pharmaceuticals. Prior to Edison, he founded Galileo Pharmaceuticals, and was its Chairman and CEO from 1995-2005. Dr. Miller was an Assistant Professor at Johns Hopkins University School of Medicine and currently holds appointments as Adjunct Professor, University of North Carolina, School of Public Health and as Clinical Instructor, Stanford University School of Medicine, where he is an attending physician in Critical Care Medicine.
About Forbes Medi-Tech Inc.
Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease. Our vision is to develop and market products along a treatment continuum that cardiovascular disease consumers, healthcare professionals and specialized cardiovascular disease research and healthcare institutions will identify, recommend and seek. Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.
# # #
For more information, please contact:
NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding the Company, its operations and future prospects, which statements can be identified by the use of forward-looking terminology such as will, prepare for, upcoming, strategy, develop, or comparable terminology referring to future events or results or terminology referring to future dates. The Companys expectations could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including uncertainty whether the U.S. Phase II trial of FM-VP4 will occur as planned or at all or will be successful; uncertainty whether FM-VP4 will be commercialized; uncertainty whether the Company will realize is strategies and vision; the need for additional clinical trials, the occurrence and success of which is not assured; intellectual property risks; the need for regulatory approvals, which are not assured and which may be denied or withdrawn; manufacturing risks and the need to manufacture to regulatory standards; product liability and insurance risks; the risk of unknown side effects; intellectual property risks; the effect of competition; and the Companys need for future funding; any of which could cause actual results to vary materially from current results or the Companys anticipated future results. See the Companys reports filed with the Canadian and U.S. securities regulatory authorities from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this News Release.